Emivirine is a failed experimental agent for the treatment of HIV. It is a non-nucleoside reverse transcriptase inhibitor.
Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
|
|
Entry/fusion inhibitors
(Discovery & development) |
- gp41 (Enfuvirtide)
- CCR5 (Maraviroc
- Vicriviroc†, Cenicriviroc†, PRO 140†)
- CD4 (Ibalizumab†)
|
|
Reverse-transcriptase
inhibitors (RTIs) |
Nucleoside &
nucleotide (NRTI)
|
- Nucleoside analogues/NARTIs: Abacavir (ABC)°#
- Emtricitabine (FTC)°#
- Lamivudine (3TC)°#
- Didanosine (ddI)#
- Zidovudine (AZT)#
- Apricitabine†
- Stampidine†
- Elvucitabine†
- Racivir†
- Amdoxovir†
- Stavudine (d4T)#
- Zalcitabine (ddC)◊
- Festinavir†
- Nucleotide analogues/NtRTIs: Tenofovir disoproxil fumarate (TDF)°#
- Tenofovir alafenamide fumarate (TAF)†
|
|
Non-nucleoside (NNRTI)
(Discovery & development)
|
- (1st generation) Efavirenz (EFV)°#
- Nevirapine (NVP)#
- Loviride◊
- Delavirdine (DLV)◊
(2nd generation) diarylpyrimidines (Etravirine
- Rilpivirine)
- Lersivirine†
|
|
|
Integrase inhibitors |
- Raltegravir°
- Elvitegravir
- Dolutegravir†
- Globoidnan A (experimental)
- MK-2048†
- BI 224436†
- GSK744†
|
|
Maturation inhibitors |
|
|
Protease Inhibitors (PI)
(Discovery and development) |
1st generation
|
- Fosamprenavir°
- Lopinavir°#
- Nelfinavir#
- Ritonavir#
- Saquinavir#
- Amprenavir◊
- Indinavir◊#
|
|
2nd generation
|
- Atazanavir°
- Darunavir°
- Tipranavir
|
|
|
Combined formulations |
- Lamivudine/zidovudine
- Emtricitabine/tenofovir/efavirenz
- Abacavir/lamivudine/zidovudine
- Tenofovir/emtricitabine
- Lopinavir/ritonavir
- Abacavir/lamivudine
- Emtricitabine/rilpivirine/tenofovir
- Elvitegravir/cobicistat/emtricitabine/tenofovir
|
|
Experimental agents |
Uncoating inhibitors
|
|
|
Transcription inhibitors
|
|
|
Translation inhibitors
|
|
|
Other
|
- Abzyme
- Calanolide A
- Ceragenin
- Cyanovirin-N
- Diarylpyrimidines
- Epigallocatechin gallate (EGCG)
- Foscarnet
- Griffithsin
- Hydroxycarbamide
- Miltefosine
- Portmanteau inhibitors
- Seliciclib†
- Synergistic enhancers
- Tre recombinase
- Zinc finger protein transcription factor
- KP-1461†
- Cobicistat†
|
|
Failed agents
|
- Dexelvucitabine
- Capravirine
- Emivirine
- Lodenosine
- Atevirdine
- Brecanavir
- Aplaviroc
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
°DHHS preferred first-line agent. ◊Formerly or rarely used agent.
M: VIR
|
virs(prot)/clss
|
cutn/syst (hppv/hiva, infl/zost/zoon)/epon
|
drug (dnaa, rnaa, rtva, vacc)
|
|
|
|